Mankind Pharma Limited

Stocks

MANKIND

INE634S01028

Delayed NSE India S.E. Other stock markets 10:50:17 22/07/2026 am IST			5-day change	1st Jan Change
2,544.20 ^INR	-1.37%		-0.12%	+15.64%

13/07	Mankind Pharma Clears Broadway Hospitality Sale, Plans Netherlands R&D Vehicle	MT
07/07	InCred Starts Mankind Pharma at Add with INR2,821 Price Target	MT

Transcript : Mankind Pharma Limited, Q4 2026 Earnings Call, May 20, 2026

Published on 05/20/2026 at 01:50 pm IST - Modified on 05/20/2026 at 09:08 pm IST

S&P Capital IQ

Add MarketScreener to your sources

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, good day, and welcome to Mankind Pharma Limited Q4 FY '26 Earnings Conference Call. [Operator Instructions] Please note that this

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Mankind Pharma Limited

13/07	Mankind Pharma Clears Broadway Hospitality Sale, Plans Netherlands R&D Vehicle	MT
07/07	InCred Starts Mankind Pharma at Add with INR2,821 Price Target	MT
02/07	BatX Energies Pvt. Ltd. announced that it has received INR 1,050 million in funding from IvyCap Ventures, Zephyr Management, L.P., JITO Angel Network and other investors	CI
08/06	Mankind Pharma Limited Announces Management Changes, Effective June 8, 2026	CI
03/06	Mankind Pharma Arm Acquires Remaining 10% Stake in Upakarma Ayurveda	MT
22/05	RUBBER-Japan futures extend falls on rising Chinese synthetic rubber supply	RE
21/05	India's top condom maker may hike prices on war-linked oil surge	RE
21/05	Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 from INR2,900, Keeps at Buy	MT
20/05	Mankind Pharma's Consolidated Profit Rises in Fiscal Q4; Shares Up 3%	MT
20/05	Mankind Pharma Limited, Q4 2026 Earnings Call, May 20, 2026
19/05	Mankind Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
19/05	Indian drugmaker Mankind posts strong quarterly profit on demand for chronic therapies	RE
19/05	Mankind Pharma March-quarter consol profit from continuing operations 5.59 billion rupees	RE
19/05	Mankind Pharma Limited Approves Realignment of Security Cover for Existing Non Convertible Debentures	CI
19/05	Mankind Pharma Limited Announces Resignation of Pramod Gokhale as Global Chief Information Officer and Senior Management Personnel, Effective May 31, 2026	CI